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Somatostatin receptors have been demonstrated on normal as well as activated human
lymphocytes in the circulation and within the reticuloendothelial system such as Peyer's
patches and the spleen [1]. Also, lymphocyte function such as proliferation and
immunoglobulin synthesis has been showed to be affected by somatostatin [2].
Following the demonstration of the presence of high-density somatostatin receptors
in a variety ofneuroendocrine derived tumors [3], Reubi et al. subsequently reported visu-
alizing non-Hodgkins lymphoma in four patients imaged with Indium-I1l-[DTPA-D-
Phel]-Octreotide, an analogue of somatostatin [4]. Autoradiography utilizing 125I-[Tyr3]-
Octreotide was used to demonstrate the diffuse distribution of somatostatin receptors in
tissue samples of biopsies taken of the involved sites.They suggested that somatostatin
receptors could be used as valuable pathobiochemical tissue markers and potentially use-
ful as an in vivo diagnostic tool for human malignant lymphomas. In ten patients studied
with malignant lymphoma (Hodgkins disease and non-Hodgkins lymphomas), lymphoma
deposits could be demonstrated [5]. In four patients, additional tumor localizations were
observed as compared to the results ofcombined physical and radiological (CT and ultra-
sound) examinations.
The role of somatostatin receptor scintigraphy (SSR)b continued to be studied by the
Rotterdam group. Forty previously untreated patients with histologically proven Hodgkins
disease and 61 untreated patients with non-Hodgkins lymphoma were consecutively stud-
ied [6]. The results of the conventional staging methods were compared to Octreotide
scintigraphy in 40 patients with proven Hodgkins disease. In 17 patients, Octreotide
scintigraphy was in agreement, in 18 patients it was superior, and in five patients, it was
inferior when compared to conventional staging methods. In seven patients, the clinical
stage was altered because of Octreotide scintigraphy, raising it in six and lowering it in
one. In the non-Hodgkins lymphoma group, 87 percent (53 of 61 patients) had positive
scan findings, and in 31 patients, there was agreement. In 17 patients, additional lesions
were revealed in Octreotide scintigraphy, which were not demonstrated by conventional
staging methods. In five patients, lesions were missed. In 13 of the 61 patients, the
Octreotide scintigraphy upgraded the stage of the disease.
The group published some of their results of 56 consecutive untreated patients with
histologically-proven Hodgkin's disease and compared the results of SSR with physical
and radiological examinations as initial evaluation [8].
Somatostatin receptor scintigraphy was positive in 55/56 (95 percent) of patients at
sites of documented disease. In 20 patients, SSR disclosed lymphoma localizations not
a To whom all correspondence should be addressed: Aldo N. Serafini, M.D., F.A.C.C., Division of
Nuclear Medicine (D-57), University of Miami School of Medicine, P.O. Box 016960, Miami, FL
33101. Tel.: (305) 243-5203; Fax: (305) 243-4913.
bAbbreviations: SSR, somatostatin based scintigraphy.
555Serafini: Somatostatin receptor scintigraphy ofmalignant lymphoma
revealed by conventional staging. As a result, in 12 patients (21 percent) scintigraphy
produced a change of stage, and in seven patients (13 percent), the additional informa-
tion obtained led to a change of treatment.
A further prospective blinded study was reported more recently by the same group
comparing SSR to conventional staging methods [7]. Ninety consecutively previously
untreated non-Hodgkins lymphoma (26 low grade, 40 intermediate grade, 21 high grade
and three unclassified) underwent scintigraphy. The patient-based analysis revealed an
overall sensitivity of 80 percent (72/90). Somatostatin receptor scintigraphy was superior
to conventional staging methods in 17 patients (19 percent). In 10 patients (11 percent),
the clinical stage was altered. In 14 patients (16 percent), some lesions were not detected.
Total agreement between conventional staging and scintigraphy was seen in 38 patients
(42 percent). On a lesion-based analysis, overall sensitivity was 66 percent (175/264).
Sensitivity was 72 percent (122/169), supradiaphragmatic, and 52 percent (44/85), infra-
diaphragmatic. Scintigraphy visualized 22 previously unknown lesions.
Wiseman et al., in a group of 10 patients studied with Indium-I111-Penteotride, found
there was agreement in the staging with conventional methods in seven ofthe 10 patients,
and staging was correctly upgraded in two patients [8]. Twenty-three of30 sites identified
by CT were identified with SSR.
Stoffel et al. performed 22 studies in 17 patients, four with Hodgkins and 13 with
lymphoma [9]. On a lesion basis, a sensitivity of 100 percent was found for Hodgkins. It
was 64 percent, 80 percent and 78 percent in low, intermediate and high grade lym-
phomas, respectively.
Although the above-mentioned studies have demonstrated promising results, this has
not been universal in the experience of other investigators.
Somatostatin receptorimaging was found to be less sensitive by Sarda et al. in study-
ing 26 patients [10]. These had histologically-proven Hodgkins in three patients and non-
Hodgkins lymphoma in 23 patients. Only 50 of the 86 (58 percent) confirmed extra-
medullary tumor sites were detected by somatostatin receptor imaging. Twelve previous-
ly unknown sites were visualized in seven patients. Tumor uptake indices measured in the
lesions were found to be highly variable and could even be normal relative to background.
As such, they felt that somatostatin receptor imaging was not reliable for the initial stag-
ing but could be useful in the diagnosis ofresidual disease after treatment.
Forty-one consecutive patients were studied by Lipp et al. [11]. Of the 34 patients
with confirmed diagnosis, 11 had Hodgkins disease, and 23 had non-Hodgkins disease.
The sensitivity for detecting Hodgkins disease was 70 percent. When broken down
according to site, this translated to 88 percent detection rate for cervical and chest involve-
ment and 13 percent for sites in the abdomen and pelvis. In non-Hodgkins lymphoma, the
sensitivity was low, 35 percent, regardless ofthe location. Forhigh-grade disease, the sen-
sitivity was 44 percent, and in low-grade disease, 29 percent. They also concluded that
Octreotide scintigraphy was better suited to characterize somatostatin expressing lym-
phomas than to localize lesion sites.
Ivancevic et al., in investigating 35 patients with Hodgkins and non-Hodgkins lym-
phoma, showed that the patient based analysis revealed an overall sensitivity of88 percent
[12]. However, the results of the lesion-based analysis demonstrated a sensitivity of 57
percent for Hodgkins disease, 43 percent for high-grade lymphomas and 35 percent for
the low-grade lymphoma. They postulated that this could be due to low receptor densities
or the presence of receptor subtypes for which pentetreotide has low affinities.
Bong et al. evaluated 35 patients who had 49 studies [13]. In the patients with
Hodgkins disease, overall sensitivity of 91 percent was reported and with non Hodgkins
lymphoma, an overall sensitivity of 37 percent. On a per lesion basis, 22 of 28 lesions
were found in the Hodgkins disease and 47 of 128 lesions for a sensitivity of 71 percent
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and 37 percent, respectively. O'Brien similarly reported a low sensitivity for non-
Hodgkins lymphoma in studying a limited number of patients [14].
Comparison with other radiopharmaceuticals has been looked at by various groups.
Cerulus et al., in comparing Gallium-67 to Indium-l 1 -Octreotide in 12 malignant lym-
phoma patients studied within two to three weeks ofeach other with both agents reported
an overall sensitivity for Ga-67 of 86 percent as compared to 71 percent for the Indium-
11 1-Octreotide [15]. They felt that both the intensity of uptake and the number was gen-
erally lower in the lesions on Octreotide scintigraphy than for the Gallium-67.
Van den Anker-Lugenburg et al. [16], on the other hand, reported a better sensitivity
for somatostatin based scintigraphy. On the overall, patient-based analysis, a sensitivity of
88 percent for SSR, compared to 63 percent for Ga-67, and on lesion-based analysis, a
sensitivity of 60 percent for SSR, as compared to 40 percent for Ga-67, was found.
Bares et al. reported first results of comparison of SSR with Indium-Ill-labeled
Octreotide and glucose metabolism measured by positron emission tomography in 22
patients with suspected or known malignant lymphoma [17]. Metabolic imaging by
positron emission tomography yielded a higher rate ofdetection oflymphoma manifesta-
tions (92 percent versus 64 percent) and better tumor contrast.
Recent studies evaluating a somatostatin analog in the treatment of lympho prolifer-
ative disorders were reported by Witzig et al. [18]. They demonstrated that 36 percent (10
of 28 patients with low-grade, non-Hodgkins lymphoma) had partial remission and 44
percent (four ofnine patients) ofpatients with cutaneous T cell non-Hodgkins lymphoma
hadpartial remissions. Since it appears that cold somatostatin at adose of 150 micrograms
every eight hours is well tolerated and has activity in these tumors, an imaging method to
recognize and follow these tumors appears to be important.
The clinical impact and cost-effectiveness of SSR in limited Hodgkin's disease was
studied in 126 previous untreated patients. Somatostatin receptor scintigraphy was com-
pared to standard staging techniques and divided into two prognostic subsets (favorable
and unfavorable prognosis) according to standard prognostic factors (e.g., age, sedimen-
tation rate, sex, B symptoms). In both subsets, SSR disclosed lesions not identified by
standard staging techniques.
In 21/37 (57 percent) ofpatients with favorable prognosis, and in 16/44 (36 percent)
ofpatients with unfavorabe prognosis, additional lesions were identified. In 11 percent of
favorable prognosis patients, the newly detected lesions were outside the subtotal nodal
irradiation field, which is the standard therapy for these patients.The authors concluded
that these patients would have been managed differently with this added information,
reducing the likelihood ofrelapse and improving life expectancy.
CONCLUSION
Encouraging reports have appeared from various investigators utilizing somatostatin
receptor based imaging. These have, in many instances, shown to be better than conven-
tional staging methods. They appear most useful in areas above the diaphragm. Although
other reports showing lower sensitivity and specificity have been reported, the reason for
these differences is notclear. Various factors may be contributing to this variability includ-
ing patient selection, limited sample size, variations in acquisition and processing proto-
cols, different doses ofradiopharmaceuticals and different levels of interpretative experi-
ence.
Whether or not SSR proves to be useful for the detection and staging of disease in
lymphoma will require further studies. The results of a recently completed multicenter
trial done in the United States has yet to be published. New information regarding factors
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influencing the presence and activity ofreceptors will enhance ourknowledge. Since pre-
liminary results showing partial response rates to cold Octreotide in the low-grade lym-
phomas have been demonstrated, these techniques will be useful as pathobiochemical tis-
sue markers to select out patients who may respond to this form of treatment.
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